Harmony Biosciences Holdings Aktie News

Sandip Kapadia sold 3,746 shares directly for a total transaction value of approximately $139,171 on Jan. 26, 2026. Kapadia had sold all of his shares in Harmony Biosciences earlier in January, but his stock options and restricted stock units vested, bringing him back into partial ownership of the company.

Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.

Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.

Harmony Biosciences has thrived due to the success of its Wakix narcolepsy treatment. Harmony is looking to extend the life of the intellectual property behind Wakix through new versions of the compound pitolisant.

Harmony's approved narcolepsy drug Wakix has been a huge financial success. Controversy and litigation surrounding Wakix have held back the stock.

The biotechnology area includes many stocks that command premium valuations because of their future prospects. So when a more attractively priced option appears, it's worth closer examination.

Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as ...